
|Articles|June 1, 2001
FDA mandates new labels for anti-fungals
Miami - The FDA last month issued a health warning concerning two popular anti-fungal drugs used to treat onychomycosis, requiring that labels for Sporanox (Janssen Pharmaceuticals) and Lamisil (Novartis) carry stronger warnings about potential liver damage. Sporanox also must warn against potential heart disease, the administration said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















